Biotech entity
All 1 tracked stories fall under one category: pharma. Of the tracked stories, 1 of 1 also mention FulcrumSec, the most common co-covered peer. The tracked stories average 2 original sources each. Thomas Willkan appears in 1 tracked Biotech story from June 17, 2026.
Last mentioned: Jun 17, 2026
Entity pulse
Coverage balance Negative coverage leads. Negative coverage exceeds positive coverage by 100 percentage points.
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
All 1 tracked stories fall under one category: pharma. Of the tracked stories, 1 of 1 also mention FulcrumSec, the most common co-covered peer. The tracked stories average 2 original sources each. Thomas Willkan appears in 1 tracked Biotech story from June 17, 2026.
Computed from the 1 stories linked to this entity, with beat comparisons drawn from all 1 Biotech stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering Thomas Willkan. Shared-story counts are live from our verified record — not editorial picks.
FulcrumSec's breach of Novo Nordisk could jeopardize years of R&D as stolen data includes proprietary information on released and unreleased drugs, trial data, and manufacturing processes. With the extortion failure and potential data sale, rival pharma firms may gain competitive intelligence, threatening Novo's market position.
Thomas Willkan is linked from 1 story on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
